{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:12:46Z","timestamp":1779192766106,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T00:00:00Z","timestamp":1562025600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T00:00:00Z","timestamp":1562025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/01792"],"award-info":[{"award-number":["PI16\/01792"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s40291-019-00409-x","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T14:06:31Z","timestamp":1562076391000},"page":"627-633","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["NFKBIZ and CW6 in Adalimumab Response Among Psoriasis Patients: Genetic Association and Alternative Transcript Analysis"],"prefix":"10.1007","volume":"23","author":[{"given":"Pablo","family":"Coto-Segura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leire","family":"Gonz\u00e1lez-Lara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Batalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noem\u00ed","family":"Eiris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rub\u00e9n","family":"Queiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliecer","family":"Coto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,2]]},"reference":[{"key":"409_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1476-4598-12-86","volume":"12","author":"B Hoesel","year":"2013","unstructured":"Hoesel B, Schmid JA. The complexity of NF-\u03baB signaling in inflammation and cancer. Mol Cancer. 2013;12:86.","journal-title":"Mol Cancer"},{"key":"409_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0898-6568(02)00080-3","volume":"15","author":"S Bell","year":"2003","unstructured":"Bell S, Degitz K, Quirling M, et al. Involvement of NF-kappaB signalling in skin physiology and disease. Cell Signal. 2003;15:1\u20137.","journal-title":"Cell Signal"},{"key":"409_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jdermsci.2012.11.002","volume":"69","author":"AM Goldminz","year":"2013","unstructured":"Goldminz AM, Au SC, Kim N, Gottlieb AB, Lizzul PF. NF-\u03baB: an essential transcription factor in psoriasis. J Dermatol Sci. 2013;69:89\u201394.","journal-title":"J Dermatol Sci"},{"key":"409_CR4","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/j.0022-202X.2005.23735.x","volume":"124","author":"PF Lizzul","year":"2005","unstructured":"Lizzul PF, Aphale A, Malaviya R, et al. Differential expression of phosphorylated NF-kappaB\/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Investig Dermatol. 2005;124:1275\u201383.","journal-title":"J Investig Dermatol"},{"key":"409_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/187221309787158399","volume":"3","author":"D Tsuruta","year":"2009","unstructured":"Tsuruta D. NF-kappaB links keratinocytes and lymphocytes in the pathogenesis of psoriasis. Recent Pat Inflamm Allergy Drug Discov. 2009;3:40\u20138.","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"409_CR6","doi-asserted-by":"publisher","first-page":"25487","DOI":"10.1074\/jbc.M111.240671","volume":"286","author":"C Johansen","year":"2011","unstructured":"Johansen C, Riis JL, Gedebjerg A, Kragballe K, Iversen L. Tumor necrosis factor alpha-mediated induction of interleukin 17C in human keratinocytes is controlled by nuclear factor kappaB. J Biol Chem. 2011;286:25487\u201394.","journal-title":"J Biol Chem"},{"key":"409_CR7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.immuni.2007.05.024","volume":"27","author":"B Rebholz","year":"2007","unstructured":"Rebholz B, Haase I, Eckelt B, et al. Crosstalk between keratinocytes and adaptive immune cells in an IkappaBalpha protein-mediated inflammatory disease of the skin. Immunity. 2007;27:296\u2013307.","journal-title":"Immunity"},{"key":"409_CR8","doi-asserted-by":"publisher","first-page":"6758","DOI":"10.1038\/sj.onc.1209943","volume":"25","author":"MS Hayden","year":"2006","unstructured":"Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene. 2006;25:6758\u201380.","journal-title":"Oncogene"},{"key":"409_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/nature02738","volume":"430","author":"M Yamamoto","year":"2004","unstructured":"Yamamoto M, Yamazaki S, Uematsu S, et al. Regulation of Toll\/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta. Nature. 2004;430:218\u201322.","journal-title":"Nature"},{"key":"409_CR10","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/nature08922","volume":"464","author":"K Okamoto","year":"2010","unstructured":"Okamoto K, Iwai Y, Oh-Hora M, et al. IkappaBzeta regulates T(H)17 development by cooperating with ROR nuclear receptors. Nature. 2010;464:1381\u20135.","journal-title":"Nature"},{"key":"409_CR11","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.jid.2016.04.012","volume":"136","author":"C Johansen","year":"2016","unstructured":"Johansen C, Bertelsen T, Ljungberg C, Mose M, Iversen L. Characterization of TNF-\u03b1- and IL-17A-mediated synergistic induction of DEFB4 gene expression in human keratinocytes through I\u03baB\u03b6. J Investig Dermatol. 2016;136:1608\u201316.","journal-title":"J Investig Dermatol"},{"key":"409_CR12","doi-asserted-by":"publisher","first-page":"E5825","DOI":"10.1073\/pnas.1509971112","volume":"112","author":"C Johansen","year":"2015","unstructured":"Johansen C, Mose M, Ommen P, et al. I\u03baB\u03b6 is a key driver in the development of psoriasis. Proc Natl Acad Sci USA. 2015;112:E5825\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"409_CR13","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/exd.13722","volume":"27","author":"T Bertelsen","year":"2018","unstructured":"Bertelsen T, Iversen L, Johansen C. The human IL-17A\/F heterodimer regulates psoriasis-associated genes through I\u03baB\u03b6. Exp Dermatol. 2018;27(9):1048\u201352.","journal-title":"Exp Dermatol"},{"key":"409_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/exd.13182","volume":"26","author":"T Bertelsen","year":"2017","unstructured":"Bertelsen T, Ljungberg C, Boye Kjellerup R, Iversen L, Johansen C. IL-17F regulates psoriasis-associated genes through I\u03baB\u03b6. Exp Dermatol. 2017;26:234\u201341. https:\/\/doi.org\/10.1111\/exd.13182 .","journal-title":"Exp Dermatol"},{"key":"409_CR15","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1038\/ncomms5331","volume":"5","author":"Y Sheng","year":"2014","unstructured":"Sheng Y, Jin X, Xu J, et al. Sequencing-based approach identified three new susceptibility loci for psoriasis. Nat Commun. 2014;5:4331.","journal-title":"Nat Commun"},{"key":"409_CR16","doi-asserted-by":"publisher","first-page":"e7001","DOI":"10.1038\/ncomms8001","volume":"6","author":"LC Tsoi","year":"2015","unstructured":"Tsoi LC, Spain SL, Ellinghaus E, et al. Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. Nat Commun. 2015;6:e7001.","journal-title":"Nat Commun"},{"key":"409_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.humimm.2017.02.008","volume":"78","author":"P Coto-Segura","year":"2017","unstructured":"Coto-Segura P, Gonzalez-Lara L, G\u00f3mez J, et al. NFKBIZ in psoriasis: assessing the association with gene polymorphisms and report of a new transcript variant. Hum Immunol. 2017;78:435\u201340.","journal-title":"Hum Immunol"},{"key":"409_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cytogfr.2014.07.016","volume":"25","author":"LM Sedger","year":"2014","unstructured":"Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants\u2014past, present and future. Cytokine Growth Factor Rev. 2014;25:453\u201372.","journal-title":"Cytokine Growth Factor Rev"},{"key":"409_CR19","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/tpj.2014.19","volume":"14","author":"S Bank","year":"2014","unstructured":"Bank S, Andersen PS, Burisch J. Associations between functional polymorphisms in the NF\u03baB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogenomics J. 2014;14:526\u201334.","journal-title":"Pharmacogenomics J"},{"key":"409_CR20","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1136\/ard.2009.117309","volume":"69","author":"C Potter","year":"2010","unstructured":"Potter C, Cordell HJ, Barton A, et al. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF-kappaB signalling pathways. Ann Rheum Dis. 2010;69:1315\u201320.","journal-title":"Ann Rheum Dis"},{"key":"409_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/tpj.2016.70","volume":"18","author":"A Batalla","year":"2018","unstructured":"Batalla A, Coto E, G\u00f3mez J, et al. IL17RA gene variants and anti-TNF response among psoriasis patients. Pharmacogenomics J. 2018;18:76\u201380.","journal-title":"Pharmacogenomics J"},{"key":"409_CR22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/FPC.0000000000000233","volume":"26","author":"G Caldarola","year":"2016","unstructured":"Caldarola G, Sgambato A, Fanali C, et al. HLA-Cw6 allele, NFkB1 and NFkBIA polymorphisms play no role in predicting response to etanercept in psoriatic patients. Pharmacogenet Genom. 2016;26:423\u20137.","journal-title":"Pharmacogenet Genom"},{"key":"409_CR23","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jaad.2015.08.055","volume":"74","author":"M Talamonti","year":"2016","unstructured":"Talamonti M, Galluzzo M, Chimenti S, Costanzo A. HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: outcome and long-term follow-up [letter]. J Am Acad Dermatol. 2016;74:374\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"409_CR24","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000441719","volume":"232","author":"M Galluzzo","year":"2016","unstructured":"Galluzzo M, Boca AN, Botti E, et al. IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis. Dermatology. 2016;232:230\u20136.","journal-title":"Dermatology"},{"issue":"6","key":"409_CR25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/FPC.0000000000000136","volume":"25","author":"A Batalla","year":"2015","unstructured":"Batalla A, Coto E, Gonz\u00e1lez-Fern\u00e1ndez D, et al. The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients. Pharmacogenet Genom. 2015;25(6):313\u20136.","journal-title":"Pharmacogenet Genom"},{"key":"409_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40291-017-0261-4","volume":"21","author":"M Talamonti","year":"2017","unstructured":"Talamonti M, Galluzzo M, Zangrilli A, et al. HLA-C*06:02 does not predispose to clinical response following long-term adalimumab treatment in psoriatic patients: a retrospective cohort study. Mol Diagn Ther. 2017;21:295\u2013301.","journal-title":"Mol Diagn Ther"},{"key":"409_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/14712598.2019.1555235","volume":"19","author":"A Silfvast-Kaiser","year":"2019","unstructured":"Silfvast-Kaiser A, Paek SY, Menter A. Anti-IL17 therapies for psoriasis. Expert Opin Biol Ther. 2019;19:45\u201354. https:\/\/doi.org\/10.1080\/14712598.2019.1555235 .","journal-title":"Expert Opin Biol Ther."},{"issue":"6","key":"409_CR28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40259-014-0098-x","volume":"28","author":"S Adami","year":"2014","unstructured":"Adami S, Cavani A, Rossi F, Girolomoni G. The role of interleukin-17A in psoriatic disease. BioDrugs. 2014;28(6):487\u201397.","journal-title":"BioDrugs"},{"key":"409_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40259-013-0035-4","volume":"27","author":"DM Roeleveld","year":"2013","unstructured":"Roeleveld DM, van Nieuwenhuijze AE, van den Berg WB, Koenders MI. The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and inflammatory disorders. BioDrugs. 2013;27:439\u201352.","journal-title":"BioDrugs"},{"key":"409_CR30","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1080\/14740338.2017.1361404","volume":"16","author":"G Murdaca","year":"2017","unstructured":"Murdaca G, Negrini S, Magnani O, Penza E, Pellecchio M, Puppo F. Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis. Expert Opin Drug Saf. 2017;16:1173\u20139.","journal-title":"Expert Opin Drug Saf"},{"key":"409_CR31","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1111\/jdv.13024","volume":"29","author":"C De Simone","year":"2015","unstructured":"De Simone C, Farina M, Maiorino A, et al. TNF-alpha gene polymorphisms can help to predict response to etanercept in psoriatic patients. J Eur Acad Dermatol Venereol. 2015;29:1786\u201390.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"409_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2217\/pgs-2017-0143","volume":"19","author":"MC Ovejero-Benito","year":"2018","unstructured":"Ovejero-Benito MC, Prieto-P\u00e9rez R, Llamas-Velasco M, et al. Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis. Pharmacogenomics. 2018;19:7\u201316.","journal-title":"Pharmacogenomics"},{"key":"409_CR33","doi-asserted-by":"publisher","first-page":"945","DOI":"10.2217\/pgs-2017-0047","volume":"18","author":"F Eektimmerman","year":"2017","unstructured":"Eektimmerman F, Swen JJ, B\u00f6hringer S, et al. Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis. Pharmacogenomics. 2017;18:945\u201353.","journal-title":"Pharmacogenomics"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-019-00409-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40291-019-00409-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-019-00409-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T19:16:06Z","timestamp":1663874166000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40291-019-00409-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,2]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["409"],"URL":"https:\/\/doi.org\/10.1007\/s40291-019-00409-x","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,2]]},"assertion":[{"value":"2 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Pablo Coto-Segura, Leire Gonz\u00e1lez-Lara, Ana Batalla, Noem\u00ed Eiris, Rub\u00e9n Queiro, and Eliecer Coto declare that they have no competing interests related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work was supported by a grant from the Spanish Instituto de Salud Carlos III-European FEDER (European Regional Development) funds (Grant PI16\/01792).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors contributed to this work by recruiting the cohort or performing the genetic and statistical analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"A summary of the data on the patients included in the study is provided as a table in the Electronic Supplementary Material.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}